{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae CMV IgG",
        "LIAISON\u00ae CMV IgG Serum Control Set"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K162969",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040290"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFZ",
        "JJX"
    ],
    "Summary Letter Date": "October 21, 2016",
    "Summary Letter Received Date": "December 8, 2016",
    "Submission Date": "October 21, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.3175"
    ],
    "Regulation Name(s)": [
        "Cytomegalovirus serological reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to human cytomegalovirus (hCMV)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer family",
        "LIAISON\u00ae XL"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Quality control material",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON CMV IgG assay and CMV IgG Serum Control Set for qualitative detection of anti-CMV IgG antibodies in human serum using CLIA on LIAISON platform.",
    "Indications for Use Summary": "Qualitative determination of IgG antibodies to human cytomegalovirus in serum as an aid in the assessment of CMV serological status and as quality control samples for assay performance monitoring on LIAISON Analyzer family.",
    "fda_folder": "Microbiology"
}